C. Ferté

发表

Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status.

Odile Casiraghi, Philippe Lambin, Charles Ferté, 2017, Oral oncology.

Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology

N. Paragios, E. Zacharaki, S. Reuzé, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Personalized radiation therapy and biomarker-driven treatment strategies: a systematic review

Jean-Emmanuel Bibault, Charles Ferté, Eric Deutsch, 2013, Cancer and Metastasis Reviews.

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.

N. Paragios, J. Soria, J. Scoazec, 2018, The Lancet. Oncology.

Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells

N. Paragios, J. Soria, R. Fietkau, 2020, Journal for ImmunoTherapy of Cancer.

Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

D. Planchard, J. Adam, J. Soria, 2018, JAMA oncology.

TumorTracer: a method to identify the tissue of origin from the somatic mutations of a tumor specimen

Zoltan Szallasi, Francesco Favero, Charles Swanton, 2015, BMC Medical Genomics.

Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial

Marie-Cécile Le Deley, Charles Ferté, Philippe Vielh, 2016, Clinical Cancer Research.

RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study.

J. Soria, F. Bidard, J. Pierga, 2017, European journal of cancer.

Abstract CT240: Molecular screening for cancer treatment optimization (MOSCATO 01): a prospective molecular triage trial; Interim analysis of 420 patients

A. Eggermont, T. Baère, F. André, 2014 .

Development and Validation of a Bedside Score to Predict Early Death in Cancer of Unknown Primary Patients

M. Sawyer, I. Ray-Coquard, P. Devos, 2009, PloS one.

Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma.

M. Copin, J. Soria, B. Besse, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

The complexity of tumor shape, spiculatedness, correlates with tumor radiomic shape features

S. Reuzé, A. Schernberg, R. Sun, 2019, Scientific Reports.

Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues.

A. Paci, F. André, J. Soria, 2011, European journal of cancer.

Tumor assessment criteria in phase I trials: beyond RECIST.

J. Soria, S. Koscielny, A. Levy, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TGR Analysis in Phase I Clinical Trials—Response

J. Soria, S. Koscielny, C. Ferté, 2014, Clinical Cancer Research.

Pemetrexed-induced pneumonitis: a case report.

J. Soria, Y. Loriot, M. Wislez, 2009, Clinical lung cancer.

Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors

A. Jimeno, J. Welsh, J. Grilley-Olson, 2020, Journal for ImmunoTherapy of Cancer.

Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial.

T. de Baère, M. Ducreux, S. Michiels, 2017, European journal of cancer.

“Classical 3 + 3 design” versus “accelerated titration designs”: analysis of 270 phase 1 trials investigating anti-cancer agents

J. Bonneterre, A. Duhamel, C. Ferté, 2009, Investigational New Drugs.

Wound healing delay after central venous access following DCF/VEGF-trap therapy

J. Soria, Y. Loriot, C. Ferté, 2009, Investigational New Drugs.

Factors associated with success of image-guided tumour biopsies: Results from a prospective molecular triage study (MOSCATO-01).

T. de Baère, F. André, G. Vassal, 2016, European Journal of Cancer.

Predictive Value of Clinical Judgment of Tumour Progression in Phase II Trials

C. Ferté, N. Penel, A. Adenis, 2012, PloS one.

High incidence of cetuximab-related infusion reactions in head and neck patients

C. Ferté, Y. Tao, F. Lemare, 2018, ESMO Open.

Life-expectancy of patients enrolled in phase 1 clinical trials: a systematic review of published prognostic models.

A. Duhamel, D. Olmos, A. Kramar, 2012, Critical reviews in oncology/hematology.

Reversible cardiogenic shock following 5-Fluorouracil infusion

J. Soria, A. Cohen, S. Ederhy, 2010, Investigational New Drugs.

FOLFIRIChemotherapy in Patients with Advanced Non Resectable Esophageal or Junctional Adenocarcinoma: A Pilot Study

C. Mariette, J. Triboulet, M. Hebbar, 2011, Journal of chemotherapy.

Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)

J. Taube, S. Jain, E. Schmidt, 2019, Journal of Immunotherapy for Cancer.

Clinical Relevance of Cardiac Iron Overload Estimated by MRI T2* in Regularly Transfused Low Risk MDS.

B. Quesnel, P. Fenaux, C. Ferté, 2006 .

Outcomes following laryngectomy refusal after insufficient response to induction chemotherapy

F. Bidault, F. Janot, P. Blanchard, 2017, The Laryngoscope.

Laryngo-esophageal Dysfunction-free Survival in a Preservation Protocol for T3 Laryngeal Squamous-cell Carcinoma.

F. Bidault, F. Janot, P. Blanchard, 2016, Anticancer research.

Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy.

D. Planchard, J. Adam, J. Soria, 2020, JCO precision oncology.

7114 Interstitial pneumonitis during RAD-001 treatment: incidence by blinded radiological analysis

J. Soria, B. Escudier, C. Caramella, 2009 .

IGF-1R Targeting Increases the Antitumor Effects of DNA-Damaging Agents in SCLC Model: An Opportunity to Increase the Efficacy of Standard Therapy

J. Bibault, J. Calderaro, J. Soria, 2013, Molecular Cancer Therapeutics.

Dysphonia induced by vascular endothelium growth factor/vascular endothelium growth factor receptor inhibitors

O. Mir, J. Soria, Y. Loriot, 2010, Investigational new drugs.

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

Charles Ferté, Laurent Dercle, Samy Ammari, 2016, Clinical Cancer Research.

Hyperprogressive disease: recognizing a novel pattern to improve patient management

J. Soria, B. Besse, C. Ferté, 2018, Nature Reviews Clinical Oncology.

Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?

M. Ducreux, V. Boige, C. Ferté, 2017, European journal of cancer.

Molecular circuits of solid tumors: prognostic and predictive tools for bedside use

F. André, J. Soria, C. Ferté, 2010, Nature Reviews Clinical Oncology.

Impact of centralization on aCGH-based genomic profiles for precision medicine in oncology.

S. Friend, J. Guinney, F. André, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients

Justin Guinney, Claus Bendtsen, Charles Ferté, 2013, Clinical Cancer Research.

A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.

H. Groen, J. Ware, K. Morrissey, 2017, European Journal of Cancer.

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.

Marie-Cécile Le Deley, Stefan Michiels, Caroline Even, 2017, Cancer discovery.

Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials

B. Bot, J. Soria, S. Koscielny, 2013, Clinical Cancer Research.

Individual Life Expectancy Estimation Using Validated Prognostic Scores for Patients with Cancer of Unknown Primary

J. Bonneterre, C. Ferté, N. Penel, 2010, Oncology.

Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types

J. Soria, C. Ferté, E. Castañón, 2020, Cancer medicine.

Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma

J. Soria, C. Ferté, J. Merchan, 2019, Investigational new drugs.

[Merkel cell carcinoma: current diagnosis and treatment].

C. Ferté, X. Mirabel, N. Penel, 2008, Bulletin du Cancer.

[Pharmacological targeting of Mdm2: rationale and perspectives for radiosensitization].

Cyrus Chargari, J. Bourhis, C. Ferté, 2011, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

The complexity of tumor shape, spiculatedness, correlates with tumor radiomic shape features

S. Reuzé, A. Schernberg, R. Sun, 2019, Scientific Reports.

Limits of radiomic-based entropy as a surrogate of tumor heterogeneity: ROI-area, acquisition protocol and tissue site exert substantial influence

Charles Ferté, Mathilde Bateson, Eric Deutsch, 2017, Scientific Reports.

Effect of tumor growth rate (TGR) on response patterns of checkpoint inhibitors in non-small cell lung cancer (NSCLC).

D. Planchard, J. Adam, J. Soria, 2016 .

Impact of Bioinformatic Procedures in the Development and Translation of High-Throughput Molecular Classifiers in Oncology

Justin Guinney, Frederic Commo, Charles Ferté, 2013, Clinical Cancer Research.

Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data.

J. Soria, S. Koscielny, B. Escudier, 2014, European urology.

Does smoking alter the mutation profile of human papillomavirus-driven head and neck cancers?

J. Soria, R. Sun, L. Lacroix, 2018, European Journal of Cancer.

Exomics and immunogenics

Charles Ferté, A. Eggermont, J. Soria, 2014, Oncoimmunology.

A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non–Small Cell Lung Cancer Based on Early Tumor Kinetics

J. Soria, S. Girish, C. Ferté, 2018, Clinical Cancer Research.

Social interactomes for enabling research communities.

Rodrigo Dienstmann, Justin Guinney, Charles Ferté, 2014, Cancer discovery.

In Focus social interactomes for enabling Research Communities

S. Friend, J. Guinney, F. McCormick, 2014 .

Abstract 2401: Circulating cell-free tumor DNA (cfDNA) analysis of 50-genes by next-generation sequencing (NGS) in the prospective MOSCATO trial

A. Eggermont, T. Baère, F. André, 2015 .

Phase II trials in patients with carcinoma of unknown primary: a pooled data analysis

C. Ferté, N. Penel, A. Adenis, 2010, Investigational New Drugs.

[Computational medical imaging (radiomics) and potential for immuno-oncology].

Cyrus Chargari, N. Paragios, E. Zacharaki, 2017, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).

J. Soria, R. Sun, L. Dercle, 2017, European journal of cancer.

Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons.

M. Ducreux, V. Boige, C. Ferté, 2015, European journal of cancer.

Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy.

J. Soria, M. Schlumberger, C. Robert, 2016, European journal of cancer.

The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy

C. Ferté, M. Mondini, C. Clémenson, 2017, Molecular Cancer Therapeutics.

Tumour growth rates and RECIST criteria in early drug development.

F. Bidault, J. Soria, S. Koscielny, 2011, European Journal of Cancer.

iRECIST: A clarification of tumour response assessment in the immunotherapy era.

C. Ferté, A. Marabelle, 2017, European journal of cancer.

Personalized radiation therapy and biomarker-driven treatment strategies: a systematic review

Cyrus Chargari, J. Bibault, J. Soria, 2013, Cancer and Metastasis Reviews.

Limits of radiomic-based entropy as a surrogate of tumor heterogeneity: ROI-area, acquisition protocol and tissue site exert substantial influence

J. Soria, L. Dercle, C. Ferté, 2017, Scientific Reports.

MA 10.11 Hyperprogressive Disease (HPD) Is Frequent in Non-Small Cell Lung Cancer (NSCLC) Patients (Pts) Treated with Anti PD1/PD-L1 Agents (IO)

D. Planchard, J. Soria, G. Tortora, 2017 .

LBA12 Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial

M. Millward, C. Ferté, Chiung-Ying Liao, 2022, Annals of Oncology.

Preliminary Results From a Phase 2 Trial of Tipifarnib in HRAS-Mutant Head and Neck Squamous Cell Carcinomas

A. Gualberto, N. Chau, C. Ferté, 2018 .

Should we resist to including tumour growth patterns in Response Evaluation Criteria in Solid Tumours evaluation? (Response to Litière et al.).

S. Koscielny, C. Ferté, L. Verlingue, 2014, European journal of cancer.

rCGH: a comprehensive array-based genomic profile platform for precision medicine

Justin Guinney, Brian M. Bot, Frederic Commo, 2015, Bioinform..

A step towards the harmonization of clinical trials inform consent forms.

C. Ferté, J. Remon, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

J. Soria, S. Koscielny, B. Escudier, 2014, European urology.

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.

N. Paragios, J. Soria, J. Scoazec, 2018, The Lancet. Oncology.

Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues.

A. Paci, F. André, J. Soria, 2011, European journal of cancer.

Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials

B. Bot, J. Soria, S. Koscielny, 2013, Clinical Cancer Research.

Abstract LB-A10: Preliminary results from a phase 2 proof of concept trial of tipifarnib in tumors with HRAS mutations

A. Ho, I. Braña, A. Gualberto, 2018 .

Trastuzumab-induced cardiotoxicity: is it time for troponin for all patients?

J. Soria, S. Ederhy, C. Ferté, 2012, American journal of clinical oncology.

Primary Colorectal Tumor Displays Differential Genomic Expression Profiles Associated with Hepatic and Peritoneal Metastases

B. Job, V. Boige, C. Ferté, 2023, Cancers.